当前位置: X-MOL 学术Eur. J. Heart Fail. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Guideline-directed medical therapy in patients undergoing transcatheter edge-to-edge repair for secondary mitral regurgitation
European Journal of Heart Failure ( IF 16.9 ) Pub Date : 2022-07-06 , DOI: 10.1002/ejhf.2613
Satoshi Higuchi 1 , Mathias Orban 1, 2 , Marianna Adamo 3 , Cristina Giannini 4 , Bruno Melica 5 , Nicole Karam 6 , Fabien Praz 7 , Daniel Kalbacher 8, 9 , Benedikt Koell 8 , Lukas Stolz 1 , Daniel Braun 1, 2 , Michael Näbauer 1 , Mirjam Wild 1, 7 , Philipp Doldi 1, 2 , Michael Neuss 10 , Christian Butter 10 , Mohammad Kassar 7 , Tobias Ruf 11 , Aniela Petrescu 11 , Sebastian Ludwig 8 , Roman Pfister 12 , Christos Iliadis 12 , Matthias Unterhuber 13 , Francisco Sampaio 5 , Diogo Ferreira 5 , Holger Thiele 13 , Stephan Baldus 12 , Ralph Stephan von Bardeleben 11 , Steffen Massberg 1, 2 , Stephan Windecker 7 , Philipp Lurz 13 , Anna Sonia Petronio 4 , JoAnn Lindenfeld 14 , William T Abraham 15 , Marco Metra 3 , Jörg Hausleiter 1, 2 ,
Affiliation  

Guideline-directed medical therapy (GDMT), based on the combination of beta-blockers (BB), renin–angiotensin system inhibitors (RASI), and mineralocorticoid receptor antagonists (MRA), is known to have a major impact on the outcome of patients with heart failure with reduced ejection fraction (HFrEF). Although GDMT is recommended prior to mitral valve transcatheter edge-to-edge repair (M-TEER), not all patients tolerate it. We studied the association of GDMT prescription with survival in HFrEF patients undergoing M-TEER for secondary mitral regurgitation (SMR).

中文翻译:

接受经导管边对边修复术治疗继发性二尖瓣反流患者的指南指导药物治疗

以 β 受体阻滞剂 (BB)、肾素-血管紧张素系统抑制剂 (RASI) 和盐皮质激素受体拮抗剂 (MRA) 联合为基础的指南指导药物治疗 (GDMT) 已知对患者的预后有重大影响伴有射血分数降低的心力衰竭 (HFrEF)。尽管在二尖瓣经导管边缘修复术 (M-TEER) 之前推荐 GDMT,但并非所有患者都能耐受。我们研究了 GDMT 处方与接受 M-TEER 治疗继发性二尖瓣反流 (SMR) 的 HFrEF 患者生存的关联。
更新日期:2022-07-06
down
wechat
bug